Resverlogix Corp. (TSE:RVX) – Equities research analysts at Zacks Investment Research increased their FY2020 earnings per share (EPS) estimates for shares of Resverlogix in a research note issued on Monday, August 5th. Zacks Investment Research analyst J. Vandermosten now anticipates that the biotechnology company will post earnings per share of ($0.29) for the year, up from their previous estimate of ($0.31).
Resverlogix (TSE:RVX) last announced its quarterly earnings results on Monday, July 29th. The biotechnology company reported C($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C($0.03) by C($0.38).
Shares of TSE RVX opened at C$2.75 on Thursday. The company’s 50-day moving average is C$2.88. The stock has a market cap of $571.63 million and a P/E ratio of -3.16. Resverlogix has a 52-week low of C$2.62 and a 52-week high of C$4.94.
In other news, Senior Officer Dr. Jan Ove Johansson sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of C$3.00, for a total transaction of C$29,979.84. Following the sale, the insider now owns 144,160 shares of the company’s stock, valued at approximately C$432,189.37.
Resverlogix Company Profile
Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases.
Featured Story: What is the downside to momentum investing?
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.